BioAge Labs Guggenheim 3rd Annual Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning, everybody. Thanks so much for joining us here at Guggenheim's Healthcare Innovation Conference. I'm Seamus Fernandez, one of the Senior Biotech Analysts here at Guggenheim. Really pleased to be joined by BioAge. Immediately to my left is Kristen Fortney, Co-founder and CEO. Kristen, maybe just to sort of kick us off, let's start off with a high-level overview of BioAge's focus and how the platform and the pipeline really support BioAge's mission in particular.
Yeah, for sure. Thanks, Seamus, for having me here today. We're pleased to be here. Looking forward to the conference. Briefly, BioAge is focused on, we have a platform based on human data, and specifically longitudinal human aging data, to find pathways and targets that are important for metabolic aging, healthy lifespans. It was that data that led us to NLRP3 as well as APJ, where we have programs running, as well as sort of preclinical collaborations and preclinical programs that we'll speak to, I think, later. Broadly, right now, our lead product is BGE-102. This is a potential best-in-class brain penetrant NLRP3 inhibitor currently in two phase II clinical trials, with data coming later this year, as well as in the second half of next year. This is a target with many different potential applications, from cardiovascular to ocular to neuro.
We're really looking forward to those imminent readouts. I'm sure we'll speak about all of that in greater depth.
Yeah. We're also really excited to be back in the clinic again soon with APJ, so we're on track to file IND by end of this year, and that's when we'll give our sort of clinical timing as well for this really exciting target that's relevant to obesity and muscle.
Great. So, just in terms of picking the targets, the longevity approach is potentially useful in picking targets. Can you talk a little bit about the approach itself and the platform?
Yeah, for sure. So what is unique about our data, and this is partially inspired by data sets like UK Biobank or deCODE Genetics that Amgen bought, have been so useful, but they are not necessarily the best data sets for understanding aging, because the length of the follow-up, like they often have longitudinal samples from people, but maybe one or two over 10 or 20 years.
Call participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
